Alfresa Holdings said on March 1 that its pharmaceutical subsidiary Alfresa Pharma has signed a licensing agreement with K Pharma, a biotech startup originating from Keio University, to develop and market ropinirole in Japan as an amyotrophic lateral sclerosis (ALS)…
To read the full story
Related Article
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
BUSINESS
- Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
- Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
- UK Clears Monthly IV Maintenance Dosing for Leqembi: Eisai/Biogen
November 14, 2025
- Kaken Gets Select-Asia Rights to Numab’s Multi-Specific Antibody
November 14, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…






